Kent Imaging Inc. is a privately held medical device company focused on commercializing the breakthrough multispectral imaging technology that assesses tissue oxygen saturation. Kent is lead by CEO Donald Chapman who has over 40 years experience in technology development and start ups and brings strong leadership in sales and international marketing. Kent’s board of directors as well as its advisory board are composed of individuals from business, medical and financial backgrounds.
Kent’s technology is based upon patented intellectual property generated internally and also licensed from the National Research Council of Canada (NRC). When developing technology, Kent designs and develops medical devices that are quick, easy to use and non-invasive. Our newest product, the Kent Multispectral Imaging device, is FDA cleared and is presently targeted to the US market but has also been sold internationally. Our technology enables improved clinical decision-making and reduces instances of incorrect diagnoses, thus resulting in optimized treatment procedures and a reduction in post-procedure corrections.